At 0.40% earnings yield versus 4.33% treasuries, ISRG requires growth miracles while insiders execute their 10th consecutive quarter of selling.
This framework suggests ISRG possesses a durable moat and generates exceptional cash, but trades at a price that requires heroic growth assumptions while insiders systematically exit.
Does this business have a durable competitive advantage?
This framework sees a strong moat built on switching costs — once a surgeon trains on da Vinci and hospitals invest in the ecosystem, changing platforms becomes prohibitively complex. The 66.4% gross margin in Q4'25, while down 160bp YoY, remains well above most medical device peers.
What cash does an owner actually get to keep?
Applying this lens reveals exceptional cash generation — the business converts nearly all accounting earnings to real cash an owner could extract. The low stock compensation relative to history suggests minimal dilution, making these owner earnings particularly attractive.
If you bought the whole business today, would the earnings justify the price?
This framework sees a magnificent business trading at an unmagnificent price. An owner buying the whole company at today's valuation would earn 0.40% on their money — roughly one-tenth the risk-free rate — betting entirely on future growth materializing.
Are managers acting like owners or hired hands?
This lens reveals concerning stewardship — management systematically reduces personal exposure while spending shareholder capital on buybacks at prices that now look expensive. The first-ever debt assumption during peak cash generation raises questions about capital allocation priorities.
This framework sees a wonderful business with a durable moat and exceptional cash generation trading at a price that makes no mathematical sense for a permanent owner. The 0.40% earnings yield requires growth rates that would make even optimistic projections blush, while insiders vote with their feet through persistent selling. Would you pay 63 times earnings for a business whose own executives are systematically reducing their exposure?
This analysis applies Warren Buffett's published investment framework to publicly available financial data. It is not authored by, endorsed by, or affiliated with Warren Buffett. Educational purposes only. Not financial advice.